Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026)
Travere Therapeutics (TVTX) reported Income from Continuing Operations of 36602000.0 for Q1 2026, up 11.22% on a YoY basis from 32910666.35 in Q1 2025, and down 66.48% quarter-over-quarter from 21986000.0 in Q4 2025.
Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Travere Therapeutics has reported Income from Continuing Operations for 16 years, with the latest figure at 36602000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 11.22% year-over-year to 36602000.0; the trailing twelve-month figure through Mar 2026 stood at 45637000.0 (up 79.8% YoY), and the FY2025 full-year result was 50261000.0, up 84.32% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 36602000.0, down from 21986000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 25706000.0 in Q3 2025, with the low at 135958000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 65605529.41 across 5 years, with a median of 80023000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 135.87% — and 2025, when it jumped 146.95%.
- Travere Therapeutics' Income from Continuing Operations stood at 85636000.0 in 2022, then decreased by 3.46% to 88596000.0 in 2023, then surged by 31.97% to 60268000.0 in 2024, then surged by 63.52% to 21986000.0 in 2025, then plunged by 66.48% to 36602000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 36602000.0 (Q1 2026), 21986000.0 (Q4 2025), and 25706000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -36.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.60 Mn |
| Dec 31, 2025 | -21.99 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.76 Mn |
| Mar 31, 2025 | -41.23 Mn |
| Dec 31, 2024 | -60.27 Mn |
| Sep 30, 2024 | -54.75 Mn |
| Jun 30, 2024 | -69.65 Mn |
| Mar 31, 2024 | -135.96 Mn |
| Dec 31, 2023 | -88.60 Mn |
| Sep 30, 2023 | -89.24 Mn |
| Jun 30, 2023 | -101.93 Mn |
| Mar 31, 2023 | -96.56 Mn |
| Dec 31, 2022 | -85.64 Mn |
| Sep 30, 2022 | -84.06 Mn |
| Jun 30, 2022 | -80.02 Mn |
| Mar 31, 2022 | -81.75 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |